The pharmacokinetic study on the interaction between nobiletin and anemarsaponin BII in vivo and in vitro

Figures & data

Figure 1. The pharmacokinetic profile of nobiletin (A) and anemarsaponin BII (B) with or without co-administration.

Table 1. Corresponding pharmacokinetic parameters of nobiletin (50 mg/kg) and anemarsaponin BII (100 mg/kg) with different pre-treatment.

	Nobiletin	Nobiletin + anemarsaponin BII	Anemarsaponin BII	Anemarsaponin BII + nobiletin
AUC (0–t) (mg/L*h)	19.57 ± 2.76	28.84 ± 1.34	3.80 ± 0.65	4.32 ± 7.78
t1/2 (h)	6.24 ± 1.53	9.80 ± 2.33	7.53 ± 1.49	7.51 ± 2.01
Tmax (h)	1.83 ± 1.17	1.17 ± 0.68	3.76 ± 0.34	4.02 ± 1.33
CL/F (L/h/kg)	2.42 ± 0.40	1.46 ± 0.26	24.20 ± 5.46	21.35 ± 5.05
Cmax (μg/L)	1767.67 ± 68.86	2309.67 ± 68.06	266.57 ± 35.56	286.74 ± 27.23

Figure 2. Effect of anemarsaponin BII on the transport of nobiletin. (A) Anemarsaponin BII and verapamil significantly suppressed the P_appBA value of nobiletin. (B) Anemarsaponin BII and verapamil showed a significant inhibitory effect on the efflux rate of nobiletin. **p < 0.01, ***p < 0.001 relative to the nobiletin alone group.

Figure 3. Effect of anemarsaponin BII on the activity of CYP3A4. (A) The activity of CYP3A4 decreased with the increasing concentration of anemarsaponin BII. (B) The IC₅₀ value of anemarsaponin BII on CYP3A4 was obtained as 10.23 μM.